Vibativ's Delayed Approval for Nosocomial Pneumonia Will Significantly Reduce Its Commercial Impact in the Methicillin-Resistant Staphylococcus Aureus Drug Market

Thursday, February 18, 2010 General News
Email Print This Page Comment
Font : A-A+

In 2018, Vibativ Will Garner Less Than Half of What it Had Been Previously Forecasted to Earn, According to New Findings from Decision Resources

For more information, contact:

Decision Resources

Decision Resources, Inc.

Gisselle Morales

Christopher Comfort

781-296-2691

781-296-2597

gmorales@dresources.com

ccomfort@dresources.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook